Active, Not Recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- GSK Investigational Site Yuma, Arizona, United States
- GSK Investigational Site Denver, Colorado, United States
- GSK Investigational Site Kansas City, Kansas, United States
- GSK Investigational Site Fairfield, Ohio, United States